Risk of cancer in patients treated with recombinant human growth hormone in childhood

Research output: Contribution to journalArticle

Abstract

Recombinant human growth hormone (GH) has been in use for over 30 years, and its indications have gradually expanded from the classical replacement therapy in GH deficiency (GHD) to pharmacological therapy in patients with normal GH secretion. The insulin-like growth factor-I (IGF-I ) is closely GH dependent and is the effector of GH biological actions in peripheral tissues. Since IGF-I has potent mitogenic and antiapoptotic effects, the use of GH, especially outside GHD, has raised safety concern regarding cancer risk. The results of experimental, epidemiological and observational studies are not univocal and a number of biases and confounders affect the interpretation of data. The aim of this review is to critically review the data linking GH therapy during childhood with cancer risk, highlighting strengths and weaknesses of the available evidence.

Original languageEnglish
Pages (from-to)92-98
Number of pages7
JournalAnnals of Pediatric Endocrinology and Metabolism
Volume24
Issue number2
DOIs
Publication statusPublished - Jun 2019

Fingerprint

Human Growth Hormone
Growth Hormone
Neoplasms
Insulin-Like Growth Factor I
Observational Studies
Epidemiologic Studies
Therapeutics
Pharmacology
Safety

Cite this

@article{c0c36d5678e84585b1d855d5dc93f3a7,
title = "Risk of cancer in patients treated with recombinant human growth hormone in childhood",
abstract = "Recombinant human growth hormone (GH) has been in use for over 30 years, and its indications have gradually expanded from the classical replacement therapy in GH deficiency (GHD) to pharmacological therapy in patients with normal GH secretion. The insulin-like growth factor-I (IGF-I ) is closely GH dependent and is the effector of GH biological actions in peripheral tissues. Since IGF-I has potent mitogenic and antiapoptotic effects, the use of GH, especially outside GHD, has raised safety concern regarding cancer risk. The results of experimental, epidemiological and observational studies are not univocal and a number of biases and confounders affect the interpretation of data. The aim of this review is to critically review the data linking GH therapy during childhood with cancer risk, highlighting strengths and weaknesses of the available evidence.",
author = "Stefano Cianfarani",
year = "2019",
month = "6",
doi = "10.6065/apem.2019.24.2.92",
language = "English",
volume = "24",
pages = "92--98",
journal = "Annals of Pediatric Endocrinology and Metabolism",
issn = "2287-1012",
publisher = "Korean society of pediatric endocrinology",
number = "2",

}

TY - JOUR

T1 - Risk of cancer in patients treated with recombinant human growth hormone in childhood

AU - Cianfarani, Stefano

PY - 2019/6

Y1 - 2019/6

N2 - Recombinant human growth hormone (GH) has been in use for over 30 years, and its indications have gradually expanded from the classical replacement therapy in GH deficiency (GHD) to pharmacological therapy in patients with normal GH secretion. The insulin-like growth factor-I (IGF-I ) is closely GH dependent and is the effector of GH biological actions in peripheral tissues. Since IGF-I has potent mitogenic and antiapoptotic effects, the use of GH, especially outside GHD, has raised safety concern regarding cancer risk. The results of experimental, epidemiological and observational studies are not univocal and a number of biases and confounders affect the interpretation of data. The aim of this review is to critically review the data linking GH therapy during childhood with cancer risk, highlighting strengths and weaknesses of the available evidence.

AB - Recombinant human growth hormone (GH) has been in use for over 30 years, and its indications have gradually expanded from the classical replacement therapy in GH deficiency (GHD) to pharmacological therapy in patients with normal GH secretion. The insulin-like growth factor-I (IGF-I ) is closely GH dependent and is the effector of GH biological actions in peripheral tissues. Since IGF-I has potent mitogenic and antiapoptotic effects, the use of GH, especially outside GHD, has raised safety concern regarding cancer risk. The results of experimental, epidemiological and observational studies are not univocal and a number of biases and confounders affect the interpretation of data. The aim of this review is to critically review the data linking GH therapy during childhood with cancer risk, highlighting strengths and weaknesses of the available evidence.

U2 - 10.6065/apem.2019.24.2.92

DO - 10.6065/apem.2019.24.2.92

M3 - Article

C2 - 31261472

VL - 24

SP - 92

EP - 98

JO - Annals of Pediatric Endocrinology and Metabolism

JF - Annals of Pediatric Endocrinology and Metabolism

SN - 2287-1012

IS - 2

ER -